Search Result
Results for "
Cardiac diseases
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
8
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0124
-
|
AD 810; CI 912
|
Carbonic Anhydrase
Apoptosis
|
Neurological Disease
|
|
Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
-
- HY-139577
-
|
IMB-1018972; IMB-101
|
Mitochondrial Metabolism
|
Cardiovascular Disease
Metabolic Disease
|
|
Ninerafaxstat (IMB-1018972) is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat can be used for research on cardiovascular diseases .
|
-
-
- HY-139577A
-
|
MB-1018972 trihydrochloride; IMB-101 trihydrochloride
|
Mitochondrial Metabolism
|
Cardiovascular Disease
Metabolic Disease
|
|
Ninerafaxstat trihydrochloride (IMB-1018972 trihydrochloride) is the trihydrochloride salt form of Ninerafaxstat (HY-139577). Ninerafaxstat trihydrochloride is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat trihydrochloride competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat trihydrochloride can be used for research on cardiovascular diseases .
|
-
-
- HY-153011
-
-
-
- HY-122605
-
|
CBA
|
TRP Channel
|
Cardiovascular Disease
Cancer
|
|
TRPM4-IN-1 (CBA) is a potent and selective inhibitor of the cation channel TRPM4, with an IC50 of 1.5 μM. TRPM4-IN-1 can be used for the research of cardiac diseases and prostate cancer .
|
-
-
- HY-12376
-
|
|
Guanylate Cyclase
|
Cardiovascular Disease
Inflammation/Immunology
|
|
BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research .
|
-
-
- HY-119238
-
-
-
- HY-B0124A
-
|
AD 810 sodium; CI 912 sodium
|
Carbonic Anhydrase
Apoptosis
|
Cardiovascular Disease
Neurological Disease
|
|
Zonisamide (AD 810) sodium is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
-
- HY-B0124R
-
|
AD 810 (Standard); CI 912 (Standard)
|
Reference Standards
Carbonic Anhydrase
Apoptosis
|
Neurological Disease
|
|
Zonisamide (Standard) is the analytical standard of Zonisamide. This product is intended for research and analytical applications. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
-
- HY-12376R
-
|
|
Guanylate Cyclase
|
Cardiovascular Disease
Inflammation/Immunology
|
|
BAY 41-2272 (Standard) is the analytical standard of BAY 41-2272. This product is intended for research and analytical applications. BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research .
|
-
-
- HY-W017540
-
|
|
ATP Synthase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
|
-
-
- HY-151483
-
|
|
Wnt
Histone Demethylase
|
Cardiovascular Disease
|
|
TK-129 is an orally active, low-toxicity, potent KDM5B inhibitor (with high affinity; IC50=44 nM). TK-129 exerts cardioprotective effects by inhibiting KDM5B and blocking the KDM5B-associated Wnt pathway. TK-129 reduces ang II-induced activation of cardiac fibroblasts in vitro and reduces isoprenaline-induced myocardial remodelling and fibrosis in vivo. TK-129 can be used in studies of cardiovascular disease .
|
-
-
- HY-147292
-
|
CK-136
|
Calcium Channel
|
Cardiovascular Disease
|
|
Nelutroctiv (CK-136) is an orally active and selective cardiac troponin activator. Nelutroctiv activates cardiac sarcomeres by enhancing the sensitivity of troponin to calcium ions and promoting the interaction between actin and myosin. Nelutroctiv enhances cardiac contractility. Nelutroctiv can be used in the researches for cardiovascular diseases with impaired cardiac contractile function .
|
-
-
- HY-105762A
-
|
Etamiphylline camsylate
|
Others
|
Cardiovascular Disease
|
|
Etamiphyllin camsylate (Etamiphylline camsylate) is a cardiac stimulant with oral activity that increases cardiac output without increasing heart rate. Etamiphyllin camsylate is also a respiratory stimulant used for respiratory failure, as Etamiphyllin camsylate relaxes the smooth muscles of the bronchi and bronchioles, thereby opening up the airways to relieve chronic obstructive pulmonary disease .
|
-
-
- HY-P10640
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
[Sar1,Thr8]-Angiotensin II is a potent angiotensin II antagonist. [Sar1,Thr8]-Angiotensin II does not alter cardiac performance. [Sar1,Thr8]-Angiotensin II might be safe for patients with cardiac disease .
|
-
![[Sar1,Thr8]-Angiotensin II](//file.medchemexpress.eu/product_pic/hy-p10640.gif)
-
- HY-P10846
-
|
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
HYNIC-CTP is a conjugate of HYNIC and CTP (cardiac-targeting peptide). HYNIC-CTP can bind with the radionuclide 99mTc through HYNIC acting as a chelator, forming 99mTc-HYNIC-CTP. 99mTc-HYNIC-CTP is specifically taken up by the heart and used for cardiac imaging, thereby facilitating research into heart diseases .
|
-
-
- HY-B1440
-
|
|
Calcium Channel
Monoamine Oxidase
|
Cardiovascular Disease
|
|
Ethaverine hydrochloride, a derivative of papaverine, inhibits cardiac L-type calcium channel. Ethaverine hydrochloride is a peripheral vasodilator and antispasmodic agent. Ethaverine hydrochloride can be used for research of peripheral vascular disease .
|
-
-
- HY-167203
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
AJG049 free base is a calcium channel (Ca 2+ channel) antagonist. AJG049 free base regulates vascular relaxation, reduces cardiac load, and improves cardiac perfusion by binding to the binding site of L-type calcium channels, specifically Diltiazem (HY-B0632). AJG049 free base can be used in cardiovascular disease research .
|
-
-
- HY-W018026
-
|
L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842
|
Acyltransferase
Apoptosis
|
Cardiovascular Disease
Metabolic Disease
|
|
Oxfenicine (L-p-Hydroxyphenylglycine) is an orally active carnitine palmitoyltransferase-1 inhibitor. Oxfenicine inhibits the oxidation of fatty acids in the heart, protecting cardiac tissue from necrotic damage during ischemia, and also has an inhibitory effect on cardiac tissue apoptosis. In addition, Oxfenicine promotes lipolysis in a high-fat diet rat model. Oxfenicine can be used in the study of cardiovascular and metabolic diseases .
|
-
-
- HY-W083373A
-
|
|
Bacterial
Autophagy
|
Cancer
|
|
3,4-Dimethoxychalcone is a Caloric restriction mimetics (CRMs). 3,4-Dimethoxychalcone induces the deacetylation of cytoplasmic proteins and stimulates autophagy flux. 3,4-Dimethoxychalcone can be used for cardiac and cancer diseases research .
|
-
-
- HY-122364
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Bucumolol hydrochloride is a β-adrenergic receptor antagonist that can slow heart rate (negative chronotropic effect) and reduce cardiac contractility (negative inotropic effect). Bucumolol hydrochloride has antiarrhythmic and local anesthetic activity and can be used in the study of cardiovascular diseases .
|
-
-
- HY-W010950
-
|
|
Potassium Channel
Sodium Channel
|
Cardiovascular Disease
|
|
Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
|
-
-
- HY-W010950A
-
|
|
Potassium Channel
Sodium Channel
|
Cardiovascular Disease
|
|
Flecainide hydrochloride is an orally active antiarrhythmic agent. Flecainide hydrochloride can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide hydrochloride can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
|
-
-
- HY-118317
-
|
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Zacopride is an orally active 5-HT3 receptor (Ki of 0.38 nM) antagonist and 5-HT4 receptor (Ki of 373 nM) agonist. Zacopride exhibits multiple activities, such as regulating gastrointestinal motility, affecting cardiac function, and exerting anxiolytic and antiemetic effects. Zacopride is currently mainly used in the research of gastrointestinal diseases, cardiovascular diseases, and psychiatric diseases such as anxiety .
|
-
-
- HY-103137
-
|
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
|
Zacopride hydrochloride is an orally active 5-HT3 receptor (Ki of 0.38 nM) antagonist and 5-HT4 receptor (Ki of 373 nM) agonist. Zacopride hydrochloride exhibits multiple activities, such as regulating gastrointestinal motility, affecting cardiac function, and exerting anxiolytic and antiemetic effects. Zacopride hydrochloride is currently mainly used in the research of gastrointestinal diseases, cardiovascular diseases, and psychiatric diseases such as anxiety .
|
-
-
- HY-B1440R
-
|
|
Reference Standards
Calcium Channel
Monoamine Oxidase
|
Cardiovascular Disease
|
|
Ethaverine (hydrochloride) (Standard) is the analytical standard of Ethaverine (hydrochloride). This product is intended for research and analytical applications. Ethaverine hydrochloride, a derivative of papaverine, inhibits cardiac L-type calcium channel. Ethaverine hydrochloride is a peripheral vasodilator and antispasmodic agent. Ethaverine hydrochloride can be used for research of peripheral vascular disease .
|
-
-
- HY-B0341
-
|
SG-75
|
Potassium Channel
|
Cardiovascular Disease
|
|
Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K + channels and cardiac ATP-sensitive K + channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .
|
-
-
- HY-101128R
-
|
FR2054 (Standard)
|
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
Ethaverine (hydrochloride) (Standard) is the analytical standard of Ethaverine (hydrochloride). This product is intended for research and analytical applications. Ethaverine hydrochloride, a derivative of papaverine, inhibits cardiac L-type calcium channel. Ethaverine hydrochloride is a peripheral vasodilator and antispasmodic agent. Ethaverine hydrochloride can be used for research of peripheral vascular disease .
|
-
-
- HY-50892
-
|
(Rac)-Seliciclib; (Rac)-CYC202
|
CDK
Apoptosis
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
Cancer
|
|
(Rac)-Roscovitine ((Rac)-Seliciclib) is a selective cyclin-dependent kinases (CDKs) inhibitor. (Rac)-Roscovitine binds to the active sites of CDKs competitively with ATP, inhibiting the phosphorylation activity of CDKs. (Rac)-Roscovitine induces apoptosis in cancer cells. (Rac)-Roscovitine is promising for research of cancers or other diseases associated with CDK dysregulation, such as neurodegenerative diseases, cardiac disorders, viral and protozoan infections, glomerulonephritis, and chronic inflammation .
|
-
-
- HY-W184837
-
|
KR-1008
|
Calcium Channel
|
Cardiovascular Disease
|
|
m-Nisoldipine (KR-1008) is a dihydropyridine calcium antagonist that can significantly increase cardiac output and heart index, significantly reduce the negative inotropic effect on the myocardium, and has a relatively high selectivity for the thoracic aorta. m-Nisoldipine can be used in the research of cardiovascular diseases .
|
-
-
- HY-B0124S2
-
|
AD 810-13C6; CI 912-13C6
|
Isotope-Labeled Compounds
Carbonic Anhydrase
Apoptosis
|
Neurological Disease
|
|
Zonisamide- 13C6 (AD 810- 13C6) is 13C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
-
- HY-W010950S
-
|
|
Potassium Channel
Sodium Channel
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
Flecainide-d3 is the deuterium labeled Flecainide. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
|
-
-
- HY-14838
-
|
BIA 5-453
|
Dopamine β-hydroxylase
|
Cardiovascular Disease
|
|
Etamicastat (BIA 5-453) is a potent and reversible dopamine-β-hydroxylase (DBH) inhibitor with an IC50 value of 107 nM . Etamicastat can be used in the research of cardiovascular diseases .
|
-
-
- HY-19679
-
|
PK 10139
|
Sodium Channel
|
Cardiovascular Disease
|
|
Quinacainol (PK 10139) is an inhibitor for sodium current with an EC50 of 95 µM. Quinacainol exhibits antiarrhythmic activity by affecting the electrophysiological properties of the heart .
|
-
-
- HY-14838A
-
|
BIA 5-453 hydrochloride
|
Dopamine β-hydroxylase
|
Cardiovascular Disease
|
|
Etamicastat hydrochloride (BIA 5-453 hydrochloride) is a potent and reversible dopamine-β-hydroxylase (DBH) inhibitor with an IC50 value of 107 nM . Etamicastat can be used in the research of cardiovascular diseases .
|
-
-
- HY-19765
-
|
|
TRP Channel
|
Cardiovascular Disease
|
|
GSK2798745 is a potent, selective, and orally active transient receptor potential vanilloid 4 (TRPV4) ion channel blocker with IC50s of 1.8 and 1.6 nM for hTRPV4 and rTRPV4, respectively. GSK2798745 can be used in cardiac and respiratory diseases research .
|
-
-
- HY-163032
-
|
|
FABP
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
FABP4-IN-3 (compound C3) is a highly selective FABP4 inhibitor (FABP4 Ki = 25 ± 3 a nM, FABP3 Ki = 15.03 μM) which exhibits a 601-fold selectivity over FABP3. FABP4-IN-3 also shows metabolic stability and potent cellular anti-inflammatory activity, making it promising to get involved in the research of metabolic disease, cardiac dysfunction and inflammation-related disease .
|
-
-
- HY-106586A
-
|
P-286 sodium
|
Biochemical Assay Reagents
|
Cardiovascular Disease
Cancer
|
|
Ioxaglate sodium (P-286 sodium) is an ionic, dimeric diagnostic contrast agent whose activity is mainly reflected in its ability to provide sufficient X-ray absorption to enhance visualization of blood vessels and other structures during imaging. Ioxaglate sodium is used to study the anatomical structure and functional status of cardiac vessels, especially in the diagnosis of coronary artery disease .
|
-
-
- HY-105351
-
|
|
Neprilysin
|
Cardiovascular Disease
|
|
CGS25155 is an orally active neutral endopeptidase 24.11 (NEP 24.11) inhibitor with an IC50 of 3 nM. CGS25155 can slow down the degradation of the cardiac hormone atrial natriuretic peptide (ANP) and exhibits antihypertensive activity in the DOCA-salt induced rat hypertension model. CGS25155 can be used in cardiovascular disease research .
|
-
-
- HY-W010950R
-
|
|
Reference Standards
Potassium Channel
Sodium Channel
|
Cardiovascular Disease
|
|
Flecainide (Standard) is the analytical standard of Flecainide. This product is intended for research and analytical applications. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
|
-
-
- HY-B0341R
-
|
SG-75 (Standard)
|
Reference Standards
Potassium Channel
|
Cardiovascular Disease
|
|
Nicorandil (Standard) is the analytical standard of Nicorandil. This product is intended for research and analytical applications. Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K + channels and cardiac ATP-sensitive K + channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .
|
-
-
- HY-B1108
-
|
AH-5158 hydrochloride; Sch-15719W
|
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Labetalol (AH5158) hydrochloride is an orally available, selective α1-adrenergic recepto and non-selective β-adrenergic receptor competitive antagonist. Labetalol hydrochloride is an antihypertensive molecule that partially crosses the blood-brain barrier and has little effect on cardiac output. Labetalol hydrochloride can be used in the study of cardiovascular diseases, such as hypertension during pregnancy .
|
-
-
- HY-121383
-
|
AH5158; Sch-15719W free base
|
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Labetalol (AH5158) is an orally available, selective α1-adrenergic recepto and non-selective β-adrenergic receptor competitive antagonist. Labetalol is an antihypertensive molecule that partially crosses the blood-brain barrier and has little effect on cardiac output. Labetalol can be used in the study of cardiovascular diseases, such as hypertension during pregnancy .
|
-
-
- HY-P5452
-
|
|
PKC
|
Others
|
|
PKCd (8-17) is a biological active peptide. (This peptide is derived from the V1 domain of protein kinase C (PKC)d. It inhibits phorbol 12-myristate 13-acetate (PMA)-induced PKCd translocation and activation. Inhibition of PKCd reduces ischemia damage in cardiac and cerebral cells, induces proliferation of fibroblasts, and inhibits graft coronary artery disease in mice.)
|
-
-
- HY-B0341S
-
|
|
Isotope-Labeled Compounds
Potassium Channel
|
Cardiovascular Disease
|
|
Nicorandil-d4 (SG-75-d4) is the deuterium labeled Nicorandil. Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K+ channels and cardiac ATP-sensitive K+ channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .
|
-
-
- HY-18282
-
|
|
LXR
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis .
|
-
-
- HY-120657
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
|
|
9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .
|
-
-
- HY-P0084
-
|
SRIF-14; Somatostatin-14
|
Endogenous Metabolite
|
Cardiovascular Disease
Neurological Disease
|
|
Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease .
|
-
-
- HY-N2263
-
Skimmin
1 Publications Verification
Umbelliferone glucoside
|
Interleukin Related
TGF-β Receptor
TNF Receptor
Parasite
|
Inflammation/Immunology
|
|
Skimmin (Umbelliferone glucoside) is a major pharmacologically active and orally active molecule present in Hydrangea paniculata, a medical herb used in traditional Chinese medicine as an anti-inflammatory agent. Skimmin has renal protective activity. Skimmin can improve creatinine clearance, and reduce plasma creatinine, and kidney injuries. Skimmin has good anti-amoebic activity against the HM1:IMMS strain of Entamoeba histolytica. Skimmin has anti-cancer and neuroprotective activities. Skimmin reduces cardiac fibrosis as well as decreasing TNF-α, IL-6, IL1β, and TGFβ1 in cardiac tissues. Skimmin can be studied in research for diabetes and diabetes-related diseases .
|
-
-
- HY-W017540S
-
|
|
Isotope-Labeled Compounds
ATP Synthase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Cancer
|
|
Cyclocreatine- 13C3 is the 13C-labeled Cyclocreatine (HY-W017540). Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
|
-
- HY-117658
-
|
|
MAP3K
|
Cardiovascular Disease
|
|
GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC50= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC50= 1 μM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue .
|
-
- HY-16910G
-
|
|
Wnt
|
Cardiovascular Disease
Cancer
|
|
WIKI4 (GMP) is WIKI4 (HY-16910) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. WIKI4 is a potent tankyrase inhibitor .
|
-
- HY-106577
-
|
Cifenline; Ro 22-7796
|
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
|
|
Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
|
-
- HY-144652
-
-
- HY-145285
-
|
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
|
|
APJ receptor agonist 5 (compound 3) is a potent and orally active agonist of apelin receptor (APJ) with an EC50 of 0.4 nM. APJ receptor agonist 5 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model. APJ receptor agonist 5 also shows an acceptable safety profile in preclinical toxicology studies. APJ receptor agonist 5 leads to improved cardiac function and can be used for researching the HF disease .
|
-
- HY-19867A
-
|
TG-0054 hydrobromide
|
CXCR
VEGFR
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Burixafor (TG-0054) hydrobromide is a selective, orally active CXCR4 antagonist that effectively blocks the interaction between CXCR4 and its ligand, stromal cell-derived factor SDF-1. Burixafor hydrobromide interferes with the SDF-1/CXCR4 signaling pathway, prompting the release of bone marrow stem cells into the peripheral circulation, exerting immunomodulatory and anti-inflammatory activities. Burixafor hydrobromide can be used in the study of cancer, Intraocular neovascular diseases (such as choroidal neovascularization), myocardial infarction and other diseases, with the potential to mobilize stem cells, improve cardiac function and reduce inflammatory responses .
|
-
- HY-145284
-
|
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
|
|
APJ receptor agonist 4 is a potent and orally active agonist of apelin receptor (APJ) with EC50 and Ki of 0.06 nM and 0.07 nM respectively. APJ receptor agonist 4 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model. APJ receptor agonist 4 also shows an acceptable safety profile in preclinical toxicology studies. APJ receptor agonist 4 leads to improved cardiac function and can be used for researching the HF disease .
|
-
- HY-121383R
-
|
AH5158 (Standard); Sch-15719W free base (Standard)
|
Reference Standards
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Labetalol (Standard) is the analytical standard of Labetalol. This product is intended for research and analytical applications. Labetalol (AH5158) is an orally available, selective α1-adrenergic recepto and non-selective β-adrenergic receptor competitive antagonist. Labetalol is an antihypertensive molecule that partially crosses the blood-brain barrier and has little effect on cardiac output. Labetalol can be used in the study of cardiovascular diseases, such as hypertension during pregnancy .
|
-
- HY-P0084R
-
|
SRIF-14 (Standard); Somatostatin-14 (Standard)
|
Adrenergic Receptor
Reference Standards
|
Cardiovascular Disease
Neurological Disease
|
|
Cyclic somatostatin (Standard) is the analytical standard of Cyclic somatostatin. This product is intended for research and analytical applications. Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease .
|
-
- HY-106577R
-
|
Cifenline (Standard); Ro 22-7796 (Standard)
|
Reference Standards
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
|
|
Cibenzoline (Standard) is the analytical standard of Cibenzoline. This product is intended for research and analytical applications. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
|
-
- HY-B1108R
-
|
AH-5158 hydrochloride(Standard); Sch-15719W (Standard)
|
Reference Standards
Adrenergic Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Labetalol hydrochloride (Standard) is the analytical standard of Labetalol hydrochloride (HY-B1108). This product is intended for research and analytical applications. Labetalol (AH5158) hydrochloride is an orally available, selective α1-adrenergic recepto and non-selective β-adrenergic receptor competitive antagonist. Labetalol hydrochloride is an antihypertensive molecule that partially crosses the blood-brain barrier and has little effect on cardiac output. Labetalol hydrochloride can be used in the study of cardiovascular diseases, such as hypertension during pregnancy .
|
-
- HY-N1570
-
-
- HY-W728545
-
|
AH5158-d6 hydrochloride; Sch-15719W-d6
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Labetalol hydrochloride-d6 (AH-5158 hydrochloride-d6) is deuterium labeled Labetalol hydrochloride (HY-B1108). Labetalol (AH5158) hydrochloride is an orally available, selective α1-adrenergic recepto and non-selective β-adrenergic receptor competitive antagonist. Labetalol hydrochloride is an antihypertensive molecule that partially crosses the blood-brain barrier and has little effect on cardiac output. Labetalol hydrochloride can be used in the study of cardiovascular diseases, such as hypertension during pregnancy .
|
-
- HY-106577S
-
|
Cifenline-d4; Ro 22-7796-d4
|
Isotope-Labeled Compounds
Potassium Channel
|
Cardiovascular Disease
Metabolic Disease
|
|
Cibenzoline-d4 (Cifenline-d4) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
|
-
- HY-B1108S
-
|
AH-5158 hydrochloride-d5; Sch-15719W-d5
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
|
Labetalol hydrochloride-d5 (AH-5158 hydrochloride-d5) is deuterium labeled Labetalol hydrochloride (HY-B1108). Labetalol (AH5158) hydrochloride is an orally available, selective α1-adrenergic recepto and non-selective β-adrenergic receptor competitive antagonist. Labetalol hydrochloride is an antihypertensive molecule that partially crosses the blood-brain barrier and has little effect on cardiac output. Labetalol hydrochloride can be used in the study of cardiovascular diseases, such as hypertension during pregnancy .
|
-
- HY-137312A
-
|
SKF 40383-A hydrochloride
|
Adrenergic Receptor
|
Inflammation/Immunology
|
|
Carbuterol (SKF 40383-A) hydrochloride is a selective β2-adrenergic receptor agonist that primarily targets bronchial smooth muscle, exhibiting significant bronchodilatory and anti-allergic activity. Carbuterol hydrochloride can directly inhibit the immunologically induced release of histamine and slow-reacting substance of anaphylaxis (SRS-A), thereby alleviating allergic responses. In addition, it exerts mild β1-mediated cardiac stimulation and is applicable to studies related to respiratory and immune-related diseases such as asthma and allergic disorders .
|
-
- HY-106577S1
-
|
Cifenline-d5; Ro 22-7796-d5
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
Metabolic Disease
|
|
Cibenzoline-d5 (Cifenline-d5) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
|
-
- HY-P10368
-
|
|
Dynamin
Reactive Oxygen Species (ROS)
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
P110 heptapeptide is a peptide inhibitor of the Drp1-Fis1 interaction. P110 heptapeptide has anti-inflammatory, immunomodulatory, mitochondrial protective, and neuroprotective activities. Without blocking the physiological functions of Drp1, P110 heptapeptide reduces pathological functions in many models of neurodegeneration, ischemia, and sepsis. P110 heptapeptide can be used for research on neurological and inflammatory diseases .
|
-
- HY-149779
-
|
|
Calcium Channel
|
Cardiovascular Disease
|
|
RyR2 stabilizer-1 (compound 12a) is a potent RyR2 stabilizer and SERCA2a activator with EC50s of 2.7 μM for RyR2 and 383 nM for SERCA2. RyR2 stabilizer-1 inhibits Ca 2+ leakage from the SR RyR2 while promoting SERCA2 to pump Ca 2+ back to SR, which make RyR2 stabilizer-1 possible to prevent cardiac arrhythmias .
|
-
- HY-N1570R
-
|
|
Reference Standards
Salt-inducible Kinase (SIK)
KLF
Amyloid-β
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
|
Pterosin B (Standard) is the analytical standard of Pterosin B (HY-N1570). This product is intended for research and analytical applications. Pterosin B is an indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces β-amyloid deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .
|
-
- HY-141645
-
|
WS070117
|
AMPK
TGF-β Receptor
NF-κB
JNK
AP-1
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis .
|
-
- HY-133019
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC50 of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently .
|
-
- HY-W005255
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
3-(3-Hydroxyphenyl)propionic acid (3HPPA) is an endothelium-dependent nitric oxide (NO) release promoter and endothelial nitric oxide synthase (eNOS) activator. 3-(3-Hydroxyphenyl)propionic acid activates eNOS to mediate vascular smooth muscle relaxation and enhances endothelial cell NO synthesis, inducing vasodilation and reducing peripheral vascular resistance. 3-(3-Hydroxyphenyl)propionic acid can dose-dependently reduce systolic and diastolic blood pressure in spontaneously hypertensive rats (SHR) without affecting cardiac contractility or heart rate. 3-(3-Hydroxyphenyl)propionic acid has antihypertensive and vascular protective effects and can be used in the prevention and treatment of cardiovascular diseases .
|
-
- HY-P1723
-
Spexin
1 Publications Verification
Neuropeptide Q
|
Neuropeptide Y Receptor
Apoptosis
Ferroptosis
Autophagy
|
Cardiovascular Disease
Neurological Disease
|
|
Spexin (Neuropeptide Q) is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin can function through both central and peripheral actions. Spexin upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
|
-
- HY-P1723A
-
|
Neuropeptide Q TFA
|
Neuropeptide Y Receptor
Apoptosis
Ferroptosis
Autophagy
|
Cardiovascular Disease
Metabolic Disease
|
|
Spexin (Neuropeptide Q) TFA is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin TFA can function through both central and peripheral actions. Spexin TFA upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin TFA improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin TFA can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
|
-
- HY-128483
-
|
|
TGF-beta/Smad
PI3K
NF-κB
Akt
Apoptosis
Dopamine β-hydroxylase
mTOR
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
|
-
- HY-121705
-
-
- HY-N0103A
-
|
|
Autophagy
Apoptosis
NF-κB
PI3K
Akt
MEK
ERK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Sophocarpine monohydrate is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine monohydrate upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine monohydrate inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine monohydrate can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine monohydrate has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .
|
-
- HY-N0103
-
Sophocarpine
Maximum Cited Publications
6 Publications Verification
|
Autophagy
Apoptosis
NF-κB
PI3K
Akt
MEK
ERK
PTEN
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .
|
-
- HY-128483R
-
|
|
TGF-beta/Smad
PI3K
NF-κB
Akt
Apoptosis
Dopamine β-hydroxylase
mTOR
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Fusaric acid (Standard) is the analytical standard of Fusaric acid (HY-128483). This product is intended for research and analytical applications. Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
|
-
- HY-N0103R
-
|
|
Reference Standards
Autophagy
Apoptosis
NF-κB
PI3K
Akt
MEK
ERK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Sophocarpine (Standard) is the analytical standard of Sophocarpine (HY-N0103). This product is intended for research and analytical applications. Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .
|
-
- HY-16734
-
|
MT-1303
|
LPL Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Amiselimod (MT-1303) is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimodis promising for research of autoimmune diseases .
|
-
- HY-16734A
-
|
MT-1303 hydrochloride
|
LPL Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Amiselimod (MT-1303) hydrochloride is converted to its active metabolite Amiselimod phosphate by sphingosine kinases in vivo. Amiselimod hydrochloride is an orally active and high selectivity sphingosine 1-phosphate receptor-1 (S1P1) agonist, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. Amiselimod hydrochloride inhibits chronic colitis via inhibiting infiltration of colitogenic Th1 and Th17 cells into the colon. Amiselimod hydrochloride inhibits lupus nephritis by reducing the infiltration of autoreactive T cells into the kidneys. Amiselimod hydrochloride is promising for research of autoimmune diseases .
|
-
-
-
HY-L118
-
|
|
157 compounds
|
|
Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion.
MCE offers a unique collection of 157 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.
|
| Cat. No. |
Product Name |
Type |
-
- HY-16910G
-
|
|
Fluorescent Dye
|
|
WIKI4 (GMP) is WIKI4 (HY-16910) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. WIKI4 is a potent tankyrase inhibitor .
|
| Cat. No. |
Product Name |
Type |
-
- HY-16910G
-
|
|
Biochemical Assay Reagents
|
|
WIKI4 (GMP) is WIKI4 (HY-16910) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. WIKI4 is a potent tankyrase inhibitor .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0084
-
|
SRIF-14; Somatostatin-14
|
Endogenous Metabolite
|
Cardiovascular Disease
Neurological Disease
|
|
Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease .
|
-
- HY-P10368
-
|
|
Dynamin
Reactive Oxygen Species (ROS)
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
|
P110 heptapeptide is a peptide inhibitor of the Drp1-Fis1 interaction. P110 heptapeptide has anti-inflammatory, immunomodulatory, mitochondrial protective, and neuroprotective activities. Without blocking the physiological functions of Drp1, P110 heptapeptide reduces pathological functions in many models of neurodegeneration, ischemia, and sepsis. P110 heptapeptide can be used for research on neurological and inflammatory diseases .
|
-
- HY-P1723
-
Spexin
1 Publications Verification
Neuropeptide Q
|
Neuropeptide Y Receptor
Apoptosis
Ferroptosis
Autophagy
|
Cardiovascular Disease
Neurological Disease
|
|
Spexin (Neuropeptide Q) is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin can function through both central and peripheral actions. Spexin upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
|
-
- HY-121705
-
-
- HY-P10640
-
|
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
[Sar1,Thr8]-Angiotensin II is a potent angiotensin II antagonist. [Sar1,Thr8]-Angiotensin II does not alter cardiac performance. [Sar1,Thr8]-Angiotensin II might be safe for patients with cardiac disease .
|
-
- HY-P10846
-
|
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
HYNIC-CTP is a conjugate of HYNIC and CTP (cardiac-targeting peptide). HYNIC-CTP can bind with the radionuclide 99mTc through HYNIC acting as a chelator, forming 99mTc-HYNIC-CTP. 99mTc-HYNIC-CTP is specifically taken up by the heart and used for cardiac imaging, thereby facilitating research into heart diseases .
|
-
- HY-P5452
-
|
|
PKC
|
Others
|
|
PKCd (8-17) is a biological active peptide. (This peptide is derived from the V1 domain of protein kinase C (PKC)d. It inhibits phorbol 12-myristate 13-acetate (PMA)-induced PKCd translocation and activation. Inhibition of PKCd reduces ischemia damage in cardiac and cerebral cells, induces proliferation of fibroblasts, and inhibits graft coronary artery disease in mice.)
|
-
- HY-P0084R
-
|
SRIF-14 (Standard); Somatostatin-14 (Standard)
|
Adrenergic Receptor
Reference Standards
|
Cardiovascular Disease
Neurological Disease
|
|
Cyclic somatostatin (Standard) is the analytical standard of Cyclic somatostatin. This product is intended for research and analytical applications. Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease .
|
-
- HY-P1723A
-
|
Neuropeptide Q TFA
|
Neuropeptide Y Receptor
Apoptosis
Ferroptosis
Autophagy
|
Cardiovascular Disease
Metabolic Disease
|
|
Spexin (Neuropeptide Q) TFA is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin TFA can function through both central and peripheral actions. Spexin TFA upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin TFA improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin TFA can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-120657
-
-
-
- HY-N2263
-
-
-
- HY-N1570
-
-
-
- HY-W005255
-
-
-
- HY-128483
-
|
|
Infection
Structural Classification
Microorganisms
Classification of Application Fields
Ketones, Aldehydes, Acids
Source classification
Disease Research Fields
|
TGF-beta/Smad
PI3K
NF-κB
Akt
Apoptosis
Dopamine β-hydroxylase
mTOR
Adrenergic Receptor
|
|
Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
|
-
-
- HY-121705
-
-
-
- HY-N0103A
-
|
|
Infection
Alkaloids
Piperidine Alkaloids
Structural Classification
Classification of Application Fields
Leguminosae
Source classification
Sophora japonica L.
Plants
Inflammation/Immunology
Disease Research Fields
|
Autophagy
Apoptosis
NF-κB
PI3K
Akt
MEK
ERK
|
|
Sophocarpine monohydrate is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine monohydrate upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine monohydrate inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine monohydrate can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine monohydrate has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .
|
-
-
- HY-N0103
-
Sophocarpine
Maximum Cited Publications
6 Publications Verification
|
Infection
Alkaloids
Piperidine Alkaloids
Structural Classification
Classification of Application Fields
Leguminosae
Source classification
Sophora flavescens Aiton
Plants
Inflammation/Immunology
Disease Research Fields
|
Autophagy
Apoptosis
NF-κB
PI3K
Akt
MEK
ERK
PTEN
|
|
Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .
|
-
-
- HY-N1570R
-
-
-
- HY-128483R
-
|
|
Structural Classification
Microorganisms
Ketones, Aldehydes, Acids
Source classification
|
TGF-beta/Smad
PI3K
NF-κB
Akt
Apoptosis
Dopamine β-hydroxylase
mTOR
Adrenergic Receptor
|
|
Fusaric acid (Standard) is the analytical standard of Fusaric acid (HY-128483). This product is intended for research and analytical applications. Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β1/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .
|
-
-
- HY-N0103R
-
|
|
Alkaloids
Piperidine Alkaloids
Structural Classification
Leguminosae
Source classification
Sophora flavescens Aiton
Plants
|
Reference Standards
Autophagy
Apoptosis
NF-κB
PI3K
Akt
MEK
ERK
|
|
Sophocarpine (Standard) is the analytical standard of Sophocarpine (HY-N0103). This product is intended for research and analytical applications. Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0341S
-
|
|
|
Nicorandil-d4 (SG-75-d4) is the deuterium labeled Nicorandil. Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K+ channels and cardiac ATP-sensitive K+ channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .
|
-
-
- HY-B0124S2
-
|
|
|
Zonisamide- 13C6 (AD 810- 13C6) is 13C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
|
-
-
- HY-W010950S
-
|
|
|
Flecainide-d3 is the deuterium labeled Flecainide. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .
|
-
-
- HY-W017540S
-
|
|
|
Cyclocreatine- 13C3 is the 13C-labeled Cyclocreatine (HY-W017540). Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
|
-
-
- HY-W728545
-
|
|
|
Labetalol hydrochloride-d6 (AH-5158 hydrochloride-d6) is deuterium labeled Labetalol hydrochloride (HY-B1108). Labetalol (AH5158) hydrochloride is an orally available, selective α1-adrenergic recepto and non-selective β-adrenergic receptor competitive antagonist. Labetalol hydrochloride is an antihypertensive molecule that partially crosses the blood-brain barrier and has little effect on cardiac output. Labetalol hydrochloride can be used in the study of cardiovascular diseases, such as hypertension during pregnancy .
|
-
-
- HY-106577S
-
|
|
|
Cibenzoline-d4 (Cifenline-d4) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
|
-
-
- HY-B1108S
-
|
|
|
Labetalol hydrochloride-d5 (AH-5158 hydrochloride-d5) is deuterium labeled Labetalol hydrochloride (HY-B1108). Labetalol (AH5158) hydrochloride is an orally available, selective α1-adrenergic recepto and non-selective β-adrenergic receptor competitive antagonist. Labetalol hydrochloride is an antihypertensive molecule that partially crosses the blood-brain barrier and has little effect on cardiac output. Labetalol hydrochloride can be used in the study of cardiovascular diseases, such as hypertension during pregnancy .
|
-
-
- HY-106577S1
-
|
|
|
Cibenzoline-d5 (Cifenline-d5) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a KATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC50 of 22.2 μM. Cibenzoline inhibits IKr and IKs currents with IC50 values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![[Sar1,Thr8]-Angiotensin II](http://file.medchemexpress.eu/product_pic/hy-p10640.gif)
